Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 153 Jul 18 – Oct 15, 2026
- Disclosed funding
- $5.2B 123 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| TB Developing nerve-targeted imaging technologies for surgery. | Undisclosed | Series A | Biotech | United States | Investors | |
| CB CORE BiomedicineCompany profile Developing the next generation of precision medicines by going beyond genomics. Developing the next generation of precision medicines by going beyond genomics. | $21M | Series A | Biotech | United States | Investors | |
| TP Torrey Pines MedicineCompany profile Develops ultra-long-acting peptide therapeutics for obesity, diabetes, and metabolic diseases Develops ultra-long-acting peptide therapeutics for obesity, diabetes, and metabolic diseases | Undisclosed | Pre-SeedPre-seed | Biotech | China | Investors | |
| VD Vivid DxCompany profile Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions Rapid infectious disease testing helping hospitals identify pathogens and guide antibiotic decisions | $15M | Seed | Biotech, Healthtech | United Kingdom | Investors | |
| M MiraeCompany profile AI-driven continuous care platform for autoimmune disease and other complex chronic conditions AI-driven continuous care platform for autoimmune disease and other complex chronic conditions | $5.4M | Seed | Biotech, Healthtech | United Kingdom | Investors | |
| MT Moa TechnologyCompany profile An agricultural biotechnology company focused on discovering novel mode of action herbicides An agricultural biotechnology company focused on discovering novel mode of action herbicides | £22.2M | Series CSeries C+ | Biotech, Agritech | United Kingdom | Investors | |
| TA Tikva AllocellCompany profile Developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors Developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors | $8M | Series A | Biotech | Singapore | Investors | |
| TB Transcripta BioCompany profile AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases | $24M | Series A | Biotech | United States | Investors | |
| CT Crystalys TherapeuticsCompany profile Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout | $130M | Series B | Biotech | United States | Investors | |
| NB N-Zyme BiomedicalCompany profile Developing first-in-class therapies targeting pepsin for reflux disease Developing first-in-class therapies targeting pepsin for reflux disease | $4.6M | Series A | Biotech | United States | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 18, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Circle Pharma, Inc., Solstice Oncology, Superluminal Medicines
8rounds2led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Oxford Science Enterprises
OMass Therapeutics, ReEmerge, Inc., Vivid Dx
5rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.